Comparison of the potency of different brands of Serenoa repens extract on 5α-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells

Pharmacology

Volumn 82, Issue 4, 2008, Pages 270-275

  Scaglione, Francesco ^a,b   Lucini, Valeria ^a   Pannacci, Marilou ^a   Caronno, Alessia ^a   Leone, Claude ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Department of Pharmacology Chemotherapy and Toxicology ^*  (Italy)

Author keywords

5 reductase activity; Benign prostatic hyperplasia; Serenoa repens

Indexed keywords

IDIPROST; ISOENZYME; PROFLUSS; PROSTAMEV; PROSTIL; SABA; SABAL EXTRACT; SERPENS; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG ISOLATION; DRUG POTENCY; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SABAL;

COCULTURE TECHNIQUES; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; ITALY; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PROSTATIC HYPERPLASIA; SERENOA; TESTOSTERONE 5-ALPHA-REDUCTASE; THERAPEUTIC EQUIVALENCY;

EID: 53449096543     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000161128     Document Type: Article

References (19)

1. Bales G, Christiano AP, Kirsh E, Gerber GS: Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 1999;54:86-89.
2. Buck AC: Phytotherapy for the prostate. Br J Urol 1996;78:325-336.
3. Di Silverio F, Flammia GP, Sciarra A, Caponera M, Mauro M, Buscarini M, Tavani M, D'Eramo G: Plant extracts in benign prostatic hyperplasia. Minerva Urol Nefrol 1993;45:143-149.
4. Wilt T, Ishani A, MacDonald R: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;3:CD001423.
5. Bayne CW, Grant ES, Chapman K, Habib FK: Characterisation of a new co-culture model for BPH which expresses 5alpha-reductase types I and II: the effects of Permixon® on DHT formation. Prostate 1999;40:232-241.
6. Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM: Human prostatic steroid 5-reductase isoforms: a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273.
7. Weisser H, Tunn S, Behnke B, Krieg M: Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28:300-306.
8. Bayne CW, Donnelly F, Chapman K, Bollina P, Buck AC, Habib FK: A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5alpha-reductase. J Clin Endocrinol Metab 1998;83:206-213.
9. Tsugaya M, Habib FK, Chisholm GD, Ross M, Tozawa K, Hayashi Y, Kohri K, Tanaka S: Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res 1996;24:265-271.
10. Habib FK: Regulation of prostate growth in culture with the pollen extract, cernitin T-60 and the impact of the drug on the EGF tissue profiles; in Vahlensick W, Rutishuaser G (eds): Benign Prostate Diseases. Stuttgart, Thieme, 1992, pp 120-128.
11. Bayne CW, Donnelly F, Ross M, Habib FK: Serenoa repens (Permixon®): a 5alpha-reductase types I and II inhibitor - new evidence in a co-culture model of BPH. Prostate 1999;40:232-241.
12. Smith CM, Ballard SA, Worman N, Buettner R, Master J: 5alpha reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996;81:1361-1366.
13. Habib FK, Wyllie MG: Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004;7:195-200.
14. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P: Effects of the lipido-sterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33:340-347.
15. Raynaud JP, Cousse H, Martin PM: Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon®. J Steroid Biochem Mol Biol 2002;82:233-239.
16. McKinney DE: Saw palmetto for benign prostatic hyperplasia. JAMA 1999;281:1699.
17. Marks LS: 5 alpha-reductase: history and clinical importance. Rev Urol 2004;6(suppl 9):S11-S21.
18. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Périer A, Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-240.
19. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP: Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41:497-507.